Ophthalmic statistics note 2: absence of evidence is not evidence of absence

Br J Ophthalmol. 2014 May;98(5):703-5. doi: 10.1136/bjophthalmol-2013-304811. Epub 2014 Mar 3.

Authors

Catey Bunce¹, Krishna V Patel, Wen Xing, Nick Freemantle, Caroline J Doré; Ophthalmic Statistics Group

Collaborators

Ophthalmic Statistics Group:
Jonathan Cook, David Crabb, Phillippa Cumberland, Gabriela Czanner, Paul Donachie, Andrew Elders, Marta Garcia-Fiñana, Rachel Nash, Neil O'Leary, Toby Prevost, Chris Rogers, Luke Saunders, Selvaraj Sivasubramanium, Irene Stratton, Joana Vasconcelos, Haogang Zhu

Affiliation

¹ NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, , London, UK.

No abstract available

Keywords: Epidemiology.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / adverse effects
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Bevacizumab
Evidence-Based Medicine / education
Gravitation
Humans
Macular Degeneration / drug therapy*
Macular Degeneration / rehabilitation
Macular Degeneration / surgery
Ophthalmology / education*
Postoperative Complications / epidemiology
Postoperative Complications / etiology
Postoperative Complications / prevention & control*
Posture
Ranibizumab
Reoperation / statistics & numerical data
Retinal Perforations / drug therapy
Retinal Perforations / rehabilitation
Retinal Perforations / surgery*
Risk Assessment
Risk Factors
Vitrectomy / adverse effects*
Vitrectomy / rehabilitation

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Bevacizumab
Ranibizumab